About Protein FAM217A
Protein FAM217A (FAM217A) is a protein
from Homo sapiens identified by UniProt accession
Q8IXS0, 508 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Protein FAM217A |
| UniProt accession | Q8IXS0 |
| Gene | FAM217A |
| Organism | Homo sapiens |
| Length | 508 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (13)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.41
- PHF-tau measurement · score 0.31
- neuroticism measurement · score 0.12
- gut microbiome measurement · score 0.09
- balding measurement · score 0.08
- neurofibrillary tangles measurement · score 0.07
- depressive symptom measurement · score 0.07
- generalized anxiety disorder · score 0.05
- metabolite measurement · score 0.04
- adolescent idiopathic scoliosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IXS0-F1 | alphafold | PREDICTED | 50.01 | — |
Amino-acid sequence (508 residues)
MGRRNENCAN SLRVSNISQE NLSHWNLDSE VPVSENKNLP AGRDGAAGGK INKNYLEIPV EQLMLEPNLS VHSQKSTQNS KQGIFQLWNC PLNEGSTIEK REFKKSSVET GFNVINHPIR VFTLNHPLTI ASVDKQVGPY PGLPMPLGLC WPYADGDFFK NRNEIHVSSC STIENNDGET LPAPNWNLKH GNSSVEENFT DESDLSENEK TNDTLLSYFK KVDLNLKPET IKNVEEPFTE EPNEVFPYPD FLPPPFSALD LHNLALSKSD NWKVTVDPAE TSVEHLITRL LELERLQHMT IQKERPRLQT TFCTPAVTER PSSSKATPKV RQPKLCDSLS LQIPCVDKSQ EKSKNNSGSC KLEQNALKRN WSNAGKYRWN SRPLSLKSSS TPKQLIETYD KNPKSSILSP CQELSFKPTI GHTNQSMVKM VSTRCLPWRS PMPVSPIPLT FPENQKEEIK APKRNFGTKK KLYRQNIVLN RPFSIQKLNC LSPSLIAKDK CCSPIEQK
Explore Protein FAM217A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets